Calreticulin mutations and long-term survival in essential thrombocythemia

Ayalew Tefferi, E. A. Wassie, T. L. Lasho, C. Finke, A. A. Belachew, R. P. Ketterling, C. A. Hanson, Animesh D Pardanani, N. Gangat, A. P. Wolanskyj

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining 12% were 'triple-negative'. We confirmed the association of mutant CALR (vs JAK2V617F) with younger age (P=0.002), male sex (P=0.01), higher platelet count (0.0004), lower hemoglobin (P<0.0001), lower leukocyte count (0.02) and lower incidence of recurrent thrombosis (0.04). Triple-negative patients were also younger than their JAK2-mutated counterparts (P=0.003) and displayed lower hemoglobin (P=0.003), lower leukocyte count (<0.0001) and lower thrombotic events (P=0.02). Median follow-up time was 12.7 years and 47% of the patients were followed until death. Survival was the longest for triple-negative and shortest for MPL-mutated patients. Median survival was 19 years for JAK2 and 20 years for CALR-mutated cases (P=0.32); the corresponding figures for patients of age ≤65 years were 26 and 32 years (P=0.56). The two mutational categories were also similar for leukemic (P=0.28) and fibrotic (P=0.28) progression rates. The current study is uniquely characterized by its very long follow-up period and provides accurate estimates of long-term survival in ET and complements current information on mutation-specific phenotype and prognosis.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.148.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - May 5 2014

Fingerprint

Calreticulin
Essential Thrombocythemia
Janus Kinase 2
Mutation
Survival
Leukocyte Count
Platelet Count
Publications
Leukemia
Thrombosis
Phenotype
Incidence

ASJC Scopus subject areas

  • Hematology
  • Anesthesiology and Pain Medicine
  • Cancer Research

Cite this

Tefferi, A., Wassie, E. A., Lasho, T. L., Finke, C., Belachew, A. A., Ketterling, R. P., ... Wolanskyj, A. P. (Accepted/In press). Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. https://doi.org/10.1038/leu.2014.148

Calreticulin mutations and long-term survival in essential thrombocythemia. / Tefferi, Ayalew; Wassie, E. A.; Lasho, T. L.; Finke, C.; Belachew, A. A.; Ketterling, R. P.; Hanson, C. A.; Pardanani, Animesh D; Gangat, N.; Wolanskyj, A. P.

In: Leukemia, 05.05.2014.

Research output: Contribution to journalArticle

Tefferi, A, Wassie, EA, Lasho, TL, Finke, C, Belachew, AA, Ketterling, RP, Hanson, CA, Pardanani, AD, Gangat, N & Wolanskyj, AP 2014, 'Calreticulin mutations and long-term survival in essential thrombocythemia', Leukemia. https://doi.org/10.1038/leu.2014.148
Tefferi, Ayalew ; Wassie, E. A. ; Lasho, T. L. ; Finke, C. ; Belachew, A. A. ; Ketterling, R. P. ; Hanson, C. A. ; Pardanani, Animesh D ; Gangat, N. ; Wolanskyj, A. P. / Calreticulin mutations and long-term survival in essential thrombocythemia. In: Leukemia. 2014.
@article{08fc809186214dbdb0f32de3400de159,
title = "Calreticulin mutations and long-term survival in essential thrombocythemia",
abstract = "The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53{\%} for Janus kinase 2 (JAK2), 32{\%} for CALR and 3{\%} for MPL; the remaining 12{\%} were 'triple-negative'. We confirmed the association of mutant CALR (vs JAK2V617F) with younger age (P=0.002), male sex (P=0.01), higher platelet count (0.0004), lower hemoglobin (P<0.0001), lower leukocyte count (0.02) and lower incidence of recurrent thrombosis (0.04). Triple-negative patients were also younger than their JAK2-mutated counterparts (P=0.003) and displayed lower hemoglobin (P=0.003), lower leukocyte count (<0.0001) and lower thrombotic events (P=0.02). Median follow-up time was 12.7 years and 47{\%} of the patients were followed until death. Survival was the longest for triple-negative and shortest for MPL-mutated patients. Median survival was 19 years for JAK2 and 20 years for CALR-mutated cases (P=0.32); the corresponding figures for patients of age ≤65 years were 26 and 32 years (P=0.56). The two mutational categories were also similar for leukemic (P=0.28) and fibrotic (P=0.28) progression rates. The current study is uniquely characterized by its very long follow-up period and provides accurate estimates of long-term survival in ET and complements current information on mutation-specific phenotype and prognosis.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.148.",
author = "Ayalew Tefferi and Wassie, {E. A.} and Lasho, {T. L.} and C. Finke and Belachew, {A. A.} and Ketterling, {R. P.} and Hanson, {C. A.} and Pardanani, {Animesh D} and N. Gangat and Wolanskyj, {A. P.}",
year = "2014",
month = "5",
day = "5",
doi = "10.1038/leu.2014.148",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Calreticulin mutations and long-term survival in essential thrombocythemia

AU - Tefferi, Ayalew

AU - Wassie, E. A.

AU - Lasho, T. L.

AU - Finke, C.

AU - Belachew, A. A.

AU - Ketterling, R. P.

AU - Hanson, C. A.

AU - Pardanani, Animesh D

AU - Gangat, N.

AU - Wolanskyj, A. P.

PY - 2014/5/5

Y1 - 2014/5/5

N2 - The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining 12% were 'triple-negative'. We confirmed the association of mutant CALR (vs JAK2V617F) with younger age (P=0.002), male sex (P=0.01), higher platelet count (0.0004), lower hemoglobin (P<0.0001), lower leukocyte count (0.02) and lower incidence of recurrent thrombosis (0.04). Triple-negative patients were also younger than their JAK2-mutated counterparts (P=0.003) and displayed lower hemoglobin (P=0.003), lower leukocyte count (<0.0001) and lower thrombotic events (P=0.02). Median follow-up time was 12.7 years and 47% of the patients were followed until death. Survival was the longest for triple-negative and shortest for MPL-mutated patients. Median survival was 19 years for JAK2 and 20 years for CALR-mutated cases (P=0.32); the corresponding figures for patients of age ≤65 years were 26 and 32 years (P=0.56). The two mutational categories were also similar for leukemic (P=0.28) and fibrotic (P=0.28) progression rates. The current study is uniquely characterized by its very long follow-up period and provides accurate estimates of long-term survival in ET and complements current information on mutation-specific phenotype and prognosis.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.148.

AB - The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining 12% were 'triple-negative'. We confirmed the association of mutant CALR (vs JAK2V617F) with younger age (P=0.002), male sex (P=0.01), higher platelet count (0.0004), lower hemoglobin (P<0.0001), lower leukocyte count (0.02) and lower incidence of recurrent thrombosis (0.04). Triple-negative patients were also younger than their JAK2-mutated counterparts (P=0.003) and displayed lower hemoglobin (P=0.003), lower leukocyte count (<0.0001) and lower thrombotic events (P=0.02). Median follow-up time was 12.7 years and 47% of the patients were followed until death. Survival was the longest for triple-negative and shortest for MPL-mutated patients. Median survival was 19 years for JAK2 and 20 years for CALR-mutated cases (P=0.32); the corresponding figures for patients of age ≤65 years were 26 and 32 years (P=0.56). The two mutational categories were also similar for leukemic (P=0.28) and fibrotic (P=0.28) progression rates. The current study is uniquely characterized by its very long follow-up period and provides accurate estimates of long-term survival in ET and complements current information on mutation-specific phenotype and prognosis.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.148.

UR - http://www.scopus.com/inward/record.url?scp=84901383293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901383293&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.148

DO - 10.1038/leu.2014.148

M3 - Article

C2 - 24791854

AN - SCOPUS:84927094466

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -